Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
46
CZMWY Quote, Financials, Valuation and Earnings
Last price:
$48.72
Seasonality move
:
8.14%
Day range:
$49.45 - $50.21
52-week range:
$44.74 - $76.28
Dividend yield:
1.3%
P/E ratio:
27.80x
P/S ratio:
1.77x
P/B ratio:
4.87x
Volume:
725
Avg. volume:
2.1K
1-year change:
0.26%
Market cap:
$4.4B
Revenue:
$2.5B
EPS (TTM):
$1.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CZMWY
Carl Zeiss Meditec AG
|
-- | -- | -- | -- | -- |
|
BNTX
BioNTech SE
|
$965.6M | -$0.07 | -24.04% | -86.85% | $137.70 |
|
CVAC
CureVac NV
|
$15.4M | -$0.11 | 0.04% | -32.36% | $5.31 |
|
EVO
Evotec SE
|
$278M | -$0.01 | 17.8% | -75.1% | $5.4436 |
|
IFRX
InflaRx NV
|
$30.8K | -$0.16 | -74.55% | -16.98% | $11.25 |
|
IMTX
Immatics NV
|
$10.9M | -$0.47 | -81.87% | -704.25% | $19.13 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CZMWY
Carl Zeiss Meditec AG
|
$49.86 | -- | $4.4B | 27.80x | $0.65 | 1.3% | 1.77x |
|
BNTX
BioNTech SE
|
$100.08 | $137.70 | $24.1B | 191.55x | $0.00 | 0% | 6.81x |
|
CVAC
CureVac NV
|
$4.66 | $5.31 | $1B | 6.52x | $0.00 | 0% | 12.94x |
|
EVO
Evotec SE
|
$3.6300 | $5.4436 | $1.3B | -- | $0.00 | 0% | 1.55x |
|
IFRX
InflaRx NV
|
$1.20 | $11.25 | $81.3M | -- | $0.00 | 0% | 370.78x |
|
IMTX
Immatics NV
|
$9.84 | $19.13 | $1.2B | 42.21x | $0.00 | 0% | 13.14x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CZMWY
Carl Zeiss Meditec AG
|
-- | -0.348 | -- | 1.10x |
|
BNTX
BioNTech SE
|
1.31% | 1.387 | 1.22% | 6.78x |
|
CVAC
CureVac NV
|
3.87% | 2.758 | 3.39% | 1.84x |
|
EVO
Evotec SE
|
37.72% | 1.418 | 44.12% | 1.05x |
|
IFRX
InflaRx NV
|
2.1% | -0.265 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 1.667 | 1.86% | 6.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CZMWY
Carl Zeiss Meditec AG
|
$328.5M | $60.2M | 7.37% | 7.44% | 8.67% | $108.3M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
EVO
Evotec SE
|
-$72.4K | -$59.7M | -11.62% | -17.7% | -31.17% | -$101.3M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
Carl Zeiss Meditec AG vs. Competitors
-
Which has Higher Returns CZMWY or BNTX?
BioNTech SE has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -1.89%. Carl Zeiss Meditec AG's return on equity of 7.44% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About CZMWY or BNTX?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BioNTech SE has an analysts' consensus of $137.70 which suggests that it could grow by 37.59%. Given that BioNTech SE has higher upside potential than Carl Zeiss Meditec AG, analysts believe BioNTech SE is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 BNTXBioNTech SE14 5 0 -
Is CZMWY or BNTX More Risky?
Carl Zeiss Meditec AG has a beta of 1.603, which suggesting that the stock is 60.293% more volatile than S&P 500. In comparison BioNTech SE has a beta of 1.393, suggesting its more volatile than the S&P 500 by 39.311%.
-
Which is a Better Dividend Stock CZMWY or BNTX?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 1.3%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or BNTX?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are smaller than BioNTech SE quarterly revenues of $1.8B. Carl Zeiss Meditec AG's net income of $32.2M is higher than BioNTech SE's net income of -$33.5M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 27.80x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.77x versus 6.81x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.77x 27.80x $623.3M $32.2M BNTXBioNTech SE6.81x 191.55x $1.8B -$33.5M
-
Which has Higher Returns CZMWY or CVAC?
CureVac NV has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -5832.47%. Carl Zeiss Meditec AG's return on equity of 7.44% beat CureVac NV's return on equity of 20.55%.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B CVACCureVac NV91.57% $1.41 $1.1B -
What do Analysts Say About CZMWY or CVAC?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 14.28%. Given that CureVac NV has higher upside potential than Carl Zeiss Meditec AG, analysts believe CureVac NV is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 CVACCureVac NV1 3 0 -
Is CZMWY or CVAC More Risky?
Carl Zeiss Meditec AG has a beta of 1.603, which suggesting that the stock is 60.293% more volatile than S&P 500. In comparison CureVac NV has a beta of 1.842, suggesting its more volatile than the S&P 500 by 84.205%.
-
Which is a Better Dividend Stock CZMWY or CVAC?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 1.3%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or CVAC?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than CureVac NV quarterly revenues of $63.3M. Carl Zeiss Meditec AG's net income of $32.2M is lower than CureVac NV's net income of $319.3M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 27.80x while CureVac NV's PE ratio is 6.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.77x versus 12.94x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.77x 27.80x $623.3M $32.2M CVACCureVac NV12.94x 6.52x $63.3M $319.3M
-
Which has Higher Returns CZMWY or EVO?
Evotec SE has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -26.29%. Carl Zeiss Meditec AG's return on equity of 7.44% beat Evotec SE's return on equity of -17.7%.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B EVOEvotec SE-0.04% -$0.14 $1.5B -
What do Analysts Say About CZMWY or EVO?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Evotec SE has an analysts' consensus of $5.4436 which suggests that it could grow by 50.53%. Given that Evotec SE has higher upside potential than Carl Zeiss Meditec AG, analysts believe Evotec SE is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 EVOEvotec SE1 0 0 -
Is CZMWY or EVO More Risky?
Carl Zeiss Meditec AG has a beta of 1.603, which suggesting that the stock is 60.293% more volatile than S&P 500. In comparison Evotec SE has a beta of 1.785, suggesting its more volatile than the S&P 500 by 78.468%.
-
Which is a Better Dividend Stock CZMWY or EVO?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 1.3%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or EVO?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than Evotec SE quarterly revenues of $191.5M. Carl Zeiss Meditec AG's net income of $32.2M is higher than Evotec SE's net income of -$50.3M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 27.80x while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.77x versus 1.55x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.77x 27.80x $623.3M $32.2M EVOEvotec SE1.55x -- $191.5M -$50.3M
-
Which has Higher Returns CZMWY or IFRX?
InflaRx NV has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -51538.49%. Carl Zeiss Meditec AG's return on equity of 7.44% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About CZMWY or IFRX?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand InflaRx NV has an analysts' consensus of $11.25 which suggests that it could grow by 837.58%. Given that InflaRx NV has higher upside potential than Carl Zeiss Meditec AG, analysts believe InflaRx NV is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 IFRXInflaRx NV5 2 0 -
Is CZMWY or IFRX More Risky?
Carl Zeiss Meditec AG has a beta of 1.603, which suggesting that the stock is 60.293% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.443, suggesting its more volatile than the S&P 500 by 44.312%.
-
Which is a Better Dividend Stock CZMWY or IFRX?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 1.3%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or IFRX?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than InflaRx NV quarterly revenues of $27.8K. Carl Zeiss Meditec AG's net income of $32.2M is higher than InflaRx NV's net income of -$14.3M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 27.80x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.77x versus 370.78x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.77x 27.80x $623.3M $32.2M IFRXInflaRx NV370.78x -- $27.8K -$14.3M
-
Which has Higher Returns CZMWY or IMTX?
Immatics NV has a net margin of 5.16% compared to Carl Zeiss Meditec AG's net margin of -974.45%. Carl Zeiss Meditec AG's return on equity of 7.44% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital CZMWYCarl Zeiss Meditec AG52.71% $0.36 $2.3B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About CZMWY or IMTX?
Carl Zeiss Meditec AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Immatics NV has an analysts' consensus of $19.13 which suggests that it could grow by 94.36%. Given that Immatics NV has higher upside potential than Carl Zeiss Meditec AG, analysts believe Immatics NV is more attractive than Carl Zeiss Meditec AG.
Company Buy Ratings Hold Ratings Sell Ratings CZMWYCarl Zeiss Meditec AG0 0 0 IMTXImmatics NV9 0 0 -
Is CZMWY or IMTX More Risky?
Carl Zeiss Meditec AG has a beta of 1.603, which suggesting that the stock is 60.293% more volatile than S&P 500. In comparison Immatics NV has a beta of 1.360, suggesting its more volatile than the S&P 500 by 35.986%.
-
Which is a Better Dividend Stock CZMWY or IMTX?
Carl Zeiss Meditec AG has a quarterly dividend of $0.65 per share corresponding to a yield of 1.3%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Carl Zeiss Meditec AG pays 18.62% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Carl Zeiss Meditec AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CZMWY or IMTX?
Carl Zeiss Meditec AG quarterly revenues are $623.3M, which are larger than Immatics NV quarterly revenues of $6.1M. Carl Zeiss Meditec AG's net income of $32.2M is higher than Immatics NV's net income of -$59.1M. Notably, Carl Zeiss Meditec AG's price-to-earnings ratio is 27.80x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Carl Zeiss Meditec AG is 1.77x versus 13.14x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CZMWYCarl Zeiss Meditec AG1.77x 27.80x $623.3M $32.2M IMTXImmatics NV13.14x 42.21x $6.1M -$59.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.
Buy
64
RVMD alert for Jan 8
Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.
